- Home
- ECBK vs KZIA Comparison
ECBK vs KZIA Comparison
Compare ECBK & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | KZIA |
|---|---|---|
| Founded | 1919 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 161.5M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | ECBK | KZIA |
|---|---|---|
| Price | $17.25 | $8.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 16.0K | ★ 306.6K |
| Earning Date | 02-04-2026 | 12-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.95 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $29,860,000.00 | $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.51 | ★ N/A |
| Revenue Growth | ★ 20.84 | N/A |
| 52 Week Low | $12.56 | $2.86 |
| 52 Week High | $17.75 | $17.40 |
Technical Indicators
Market Signals| Indicator | ECBK | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 41.80 |
| Support Level | $17.15 | $6.65 |
| Resistance Level | $17.55 | $11.06 |
| Average True Range (ATR) | 0.25 | 2.08 |
| MACD | -0.01 | -0.59 |
| Stochastic Oscillator | 84.85 | 12.56 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.